MarketCap
Facebook
X
Telegram
Sonnet BioTherapeutics Holdings Balance Sheet 2025-2009 | SONN
Brief overview of Sonnet BioTherapeutics Holdings's financial position
Balance sheet changes are traced across five available annual reports between 2021 and 2025.
Assets fell from $29 million to $14.9 million. This may reflect either deliberate optimization or a reduction in business scale.
Liabilities expanded faster than the asset base, -39.2% versus -48.7%. Debt-service capacity deserves attention.
The equity ratio reached 72.5% from 76.8%. A high capital share reduces dependence on liabilities.
Cash equals 34.4% of the balance sheet, compared with 95.3% five periods ago. This is the readily available cushion.
Retained earnings are negative at -$133.7 million. This reduces the formal capital cushion, although large shareholder returns may have contributed.
Overall picture
Sonnet BioTherapeutics Holdings's balance sheet presents a mixed picture: strengths coexist with a limited cushion. Future capital and debt trends are particularly important.
Annual Balance Sheet Sonnet BioTherapeutics Holdings
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | -18.6 K | -2.07 M | -2.8 M | -27.5 M | -7.35 M | 182 K | 6.15 M | 3.58 M | 10.1 M | 7.82 M | 6.58 M | 436 K | -1.22 M | 1.24 M | 890 K | - |
Long Term Debt |
- | 46.6 K | 131 K | 204 K | 30.6 K | - | - | 3.67 M | 852 K | 4.22 M | 1.11 M | 5.01 M | 179 K | - | 236 K | 686 K | - |
Long Term Debt Current |
46.6 K | 84.3 K | 73 K | 51.3 K | 94.5 K | 82.1 K | 3.3 M | 3.74 M | 5.74 M | 6.17 M | 5.38 M | 1.81 M | 700 K | 236 K | 1.17 M | 250 K | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | 9.34 M | 4.57 M | 8.46 M | 4.66 M | 7.89 M | 2.79 M | 345 K | 592 K | - | - |
Total Current Liabilities |
4.1 M | 3.21 M | 5.52 M | 8.16 M | 6.7 M | 4.72 M | 18.1 M | 14.3 M | 14.9 M | 12.1 M | 16.2 M | 11.4 M | 5.53 M | 1.77 M | 3.72 M | 646 K | - |
Total Liabilities |
4.1 M | 3.26 M | 5.66 M | 8.37 M | 6.73 M | 4.97 M | 2.89 M | 22.4 M | 19.5 M | 20.6 M | 20.8 M | 20.8 M | 8.85 M | 2.12 M | 4.31 M | 1.33 M | - |
Deferred Revenue |
- | - | - | - | - | 500 K | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-134 M | -118 M | -110 M | -91.4 M | -61.7 M | - | -12.4 M | -57.1 M | -49.1 M | -42.2 M | -33 M | -20.9 M | -14.5 M | -9.26 M | -6.09 M | -4.93 M | - |
Total Assets |
14.9 M | 2.77 M | 5.43 M | 5.83 M | 29 M | 7.99 M | 39.8 K | 29.8 M | 30.2 M | 33.5 M | 42.2 M | 35.8 M | 20.1 M | 7.65 M | 4.8 M | 1.41 M | - |
Cash and Cash Equivalents |
5.12 M | 149 K | 2.27 M | 3.05 M | 27.6 M | 7.35 M | 501 K | 630 K | 273 K | 269 K | 1.53 M | 246 K | 443 K | 1.25 M | 152 K | 46 K | 2.37 K |
Book Value |
10.8 M | -486 K | -226 K | -2.54 M | 22.3 M | 3.02 M | -2.85 M | 7.43 M | 10.7 M | 12.9 M | 21.4 M | 15 M | 11.2 M | 5.53 M | 486 K | 82.4 K | - |
Total Shareholders Equity |
10.8 M | -486 K | -226 K | -2.54 M | 22.3 M | 3.02 M | -3.61 M | 7.43 M | 10.7 M | 12.6 M | 21.8 M | 15 M | 11.2 M | 5.53 M | 486 K | 82.4 K | 718 K |
All numbers in USD currency
Quarterly Balance Sheet Sonnet BioTherapeutics Holdings
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
46.6 K | 46.6 K | - | 23.6 K | 46.6 K | 68.8 K | 23.6 K | 111 K | 131 K | 150 K | 169 K | 187 K | 204 K | 221 K | - | 5 K | 30.6 K | 55.5 K | 30.6 K | 103 K | 125 K | 125 K | 6.35 M | 6.63 M | 6.68 M | 6.62 M | 6.77 M | 3 M | 3 M | 3 M | 3 M | 5.74 M | 5.14 M | 4.53 M | 6.01 M | 287 K | 287 K | 287 K | 287 K | 1.1 M | 1.1 M | 1.1 M | 5.65 M | 5.01 M | 5.01 M | 5.01 M | 5.01 M | 399 K | 399 K | 399 K | 399 K | - | - | 232 K | 233 K | 236 K | 236 K | 236 K | 236 K |
Total Liabilities |
5.1 M | 3.17 M | 3.17 M | 3.15 M | 3.26 M | 3.18 M | 3.15 M | 2.77 M | 5.66 M | 6.62 M | 7.94 M | 8.48 M | 8.37 M | 6.73 M | 6.51 M | 4.35 M | 6.73 M | 5.81 M | 6.73 M | 5.52 M | 4.97 M | 4.97 M | 4.97 M | 34.7 M | 2.89 M | 38.5 M | 41.1 M | 21.5 M | 21.5 M | 21.5 M | 21.5 M | 18.7 M | 18.7 M | 18.7 M | 18.7 M | 19.8 M | 19.8 M | 19.8 M | 19.8 M | 20.4 M | 20.4 M | 20.4 M | 20.4 M | 20.8 M | 20.8 M | 20.8 M | 20.8 M | 8.85 M | 8.85 M | 8.85 M | 8.85 M | 2.12 M | 2.12 M | 2.12 M | 2.12 M | 4.31 M | 4.31 M | 4.31 M | 4.31 M |
Retained Earnings |
-128 M | -124 M | -124 M | -121 M | -118 M | -115 M | -121 M | -111 M | -110 M | -107 M | -103 M | -97 M | -91.4 M | -84 M | -76.1 M | -67.9 M | -61.7 M | -54.7 M | -61.7 M | -42.6 M | -36.7 M | -36.7 M | -36.7 M | -75.1 M | -12.4 M | -62.3 M | -59 M | -57.1 M | -57.1 M | -57.1 M | -57.1 M | -49.1 M | -49.1 M | -49.1 M | -49.1 M | -42.2 M | -42.2 M | -42.2 M | -42.2 M | -33 M | -33 M | -33 M | -33 M | -20.9 M | -20.9 M | -20.9 M | -20.9 M | -14.5 M | -14.5 M | -14.5 M | -14.5 M | -9.26 M | -9.26 M | -9.26 M | -9.26 M | -6.09 M | -6.09 M | -6.09 M | -6.09 M |
Total Assets |
2.06 M | 3.84 M | 3.84 M | 7.18 M | 2.77 M | 5.8 M | 7.18 M | 5.34 M | 5.43 M | 10 M | 13.3 M | 4.94 M | 5.83 M | 7.49 M | 15 M | 20.7 M | 29 M | 7.18 M | 29 M | 3.03 M | 7.99 M | 7.99 M | 7.99 M | 31.5 M | 39.8 K | 45.4 M | 48.1 M | 29.8 M | 29.8 M | 29.8 M | 29.8 M | 30.2 M | 30.2 M | 30.2 M | 30.2 M | 33.5 M | 33.5 M | 33.5 M | 33.5 M | 42.2 M | 42.2 M | 42.2 M | 42.2 M | 35.8 M | 35.8 M | 35.8 M | 35.8 M | 20.1 M | 20.1 M | 20.1 M | 20.1 M | 7.65 M | 7.65 M | 7.65 M | 7.65 M | 4.8 M | 4.8 M | 4.8 M | 4.8 M |
Cash and Cash Equivalents |
321 K | 2.06 M | 2.06 M | 4.86 M | 149 K | 3.55 M | 4.86 M | 3.02 M | 2.27 M | 7.02 M | 11.4 M | 1.7 M | 3.05 M | 5.22 M | 13.6 M | 19.4 M | 27.6 M | 6.04 M | 27.6 M | 2.35 M | 7.35 M | 7.35 M | 7.35 M | 501 K | 35.7 K | 579 K | 562 K | 524 K | 630 K | 630 K | 630 K | 273 K | 273 K | 273 K | 273 K | 269 K | 269 K | 269 K | 1.18 M | 1.53 M | 1.81 M | 2.81 M | 3.32 M | 246 K | 246 K | 246 K | 246 K | 443 K | 443 K | 443 K | 443 K | 1.22 M | 1.22 M | 1.22 M | 1.22 M | 165 K | 165 K | 152 K | 152 K |
Book Value |
-3.05 M | 662 K | 662 K | 4.04 M | -486 K | 2.62 M | 4.04 M | 2.57 M | -226 K | 3.42 M | 5.37 M | -3.54 M | -2.54 M | 764 K | 8.53 M | 16.4 M | 22.3 M | 1.37 M | 22.3 M | -2.49 M | 3.02 M | 3.02 M | 3.02 M | -3.15 M | -2.85 M | 6.92 M | 6.96 M | 8.26 M | 8.26 M | 8.26 M | 8.26 M | 11.5 M | 11.5 M | 11.5 M | 11.5 M | 13.7 M | 13.7 M | 13.7 M | 13.7 M | 21.8 M | 21.8 M | 21.8 M | 21.8 M | 15 M | 15 M | 15 M | 15 M | 11.2 M | 11.2 M | 11.2 M | 11.2 M | 5.53 M | 5.53 M | 5.53 M | 5.53 M | 486 K | 486 K | 486 K | 486 K |
Total Shareholders Equity |
-3.05 M | 662 K | 662 K | 4.04 M | -486 K | 2.62 M | 4.04 M | 2.57 M | -226 K | 3.42 M | 5.37 M | -3.54 M | -2.54 M | 764 K | 8.53 M | 16.4 M | 22.3 M | 1.37 M | 2.02 M | -2.49 M | -2.49 M | -2.49 M | -2.49 M | -2.4 M | -2.85 M | 6.01 M | -3.61 M | 7.43 M | 7.43 M | 7.43 M | 7.43 M | 10.7 M | 10.7 M | 10.7 M | 10.7 M | 12.6 M | 12.6 M | 12.6 M | 12.6 M | 21.4 M | 21.8 M | 21.8 M | 21.8 M | 15 M | 15 M | 15.6 M | 15.1 M | 11.2 M | 9.21 M | 11.2 M | 11.2 M | 5.53 M | 5.53 M | 5.53 M | 5.53 M | 486 K | 486 K | 486 K | 486 K |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Sonnet BioTherapeutics Holdings, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Canada
China
Israel
France
Germany
Britain
Russia
Belgium
Cayman-islands
